HK1107977A1 - Triazole derivative - Google Patents
Triazole derivativeInfo
- Publication number
- HK1107977A1 HK1107977A1 HK07113536.7A HK07113536A HK1107977A1 HK 1107977 A1 HK1107977 A1 HK 1107977A1 HK 07113536 A HK07113536 A HK 07113536A HK 1107977 A1 HK1107977 A1 HK 1107977A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- triazole derivative
- triazole
- derivative
- Prior art date
Links
- 150000003852 triazoles Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004228394 | 2004-08-04 | ||
JP2005121769 | 2005-04-20 | ||
PCT/JP2005/014351 WO2006013948A1 (ja) | 2004-08-04 | 2005-08-04 | トリアゾール誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1107977A1 true HK1107977A1 (en) | 2008-04-25 |
Family
ID=35787227
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07113536.7A HK1107977A1 (en) | 2004-08-04 | 2007-12-12 | Triazole derivative |
Country Status (7)
Country | Link |
---|---|
US (1) | US8022225B2 (ru) |
EP (1) | EP1798226A4 (ru) |
JP (1) | JP4993407B2 (ru) |
CN (1) | CN1993333B (ru) |
HK (1) | HK1107977A1 (ru) |
RU (1) | RU2383536C2 (ru) |
WO (1) | WO2006013948A1 (ru) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1993333B (zh) | 2004-08-04 | 2012-08-01 | 大正制药株式会社 | 三唑衍生物 |
CA2580409C (en) * | 2004-09-16 | 2013-08-13 | Astellas Pharma Inc. | Triazole derivative or salt thereof |
US7829589B2 (en) | 2005-06-10 | 2010-11-09 | Elixir Pharmaceuticals, Inc. | Sulfonamide compounds and uses thereof |
TW200736234A (en) * | 2006-01-17 | 2007-10-01 | Astrazeneca Ab | Chemical compounds |
US8022091B2 (en) | 2006-02-03 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd. | Triazole derivative |
EP1988081B1 (en) * | 2006-02-06 | 2012-10-17 | Taisho Pharmaceutical Co., Ltd | Binding inhibitor of sphingosine-1-phosphate |
MX2008011723A (es) * | 2006-03-16 | 2008-09-26 | Astellas Pharma Inc | Derivado de triazol o su sal. |
JP2009534365A (ja) * | 2006-04-21 | 2009-09-24 | アストラゼネカ アクチボラグ | Adg受容体修飾物質として有用なスルホンアミド化合物 |
US20090105324A1 (en) * | 2006-04-21 | 2009-04-23 | Astrazeneca Ab | Imidazole derivatives for use as edg-1 antagonists |
TW200827340A (en) * | 2006-11-10 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
WO2008059238A1 (en) * | 2006-11-17 | 2008-05-22 | Astrazeneca Ab | Benzenesulfonamide compounds as edg-1 antagonists useful in the treatment of cancer |
WO2009017219A1 (ja) * | 2007-08-01 | 2009-02-05 | Taisho Pharmaceutical Co., Ltd. | S1p1結合阻害物質 |
EP2262528A2 (en) * | 2008-02-25 | 2010-12-22 | Expression Drug Designs, Llc. | Sphingosine 1-phosphate antagonism |
US8212010B2 (en) | 2008-02-25 | 2012-07-03 | Expression Drug Designs, Llc | Sphingosine 1-phosphate antagonism |
HUE031419T2 (en) | 2008-07-03 | 2017-07-28 | Astellas Pharma Inc | Triazole derivative or salt |
HUE030424T2 (en) | 2008-07-23 | 2017-05-29 | Arena Pharm Inc | Substituted 1,2,3,4-tetrahydrocyclopenta [b] indol-3-ylacetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
SI2342205T1 (sl) | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
ES2937386T3 (es) | 2010-01-27 | 2023-03-28 | Arena Pharm Inc | Procesos para la preparación de ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclopenta[b]indol-3-il)acético y sales del mismo |
WO2011109471A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
CA2794854A1 (en) | 2010-04-06 | 2011-10-13 | Heliae Development, Llc | Methods of and systems for producing biofuels |
WO2014124209A1 (en) | 2013-02-08 | 2014-08-14 | General Mills, Inc. | Reduced sodium food products |
CN103275013A (zh) * | 2013-05-27 | 2013-09-04 | 云南大学 | 一种新型含氮杂环磺酰胺衍生物型芳香化酶抑制剂及其制备方法 |
EP3242666A1 (en) | 2015-01-06 | 2017-11-15 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
JP6838744B2 (ja) | 2015-06-22 | 2021-03-03 | アリーナ ファーマシューティカルズ, インコーポレイテッド | S1P1レセプター関連障害における使用のための(R)−2−(7−(4−シクロペンチル−3−(トリフルオロメチル)ベンジルオキシ)−1,2,3,4−テトラヒドロシクロペンタ[b]インドール−3−イル)酢酸(化合物1)の結晶性L−アルギニン塩 |
EP3210469A1 (de) | 2016-02-23 | 2017-08-30 | Bayer Cropscience AG | Verwendung von substituierten thio-1,2,4-triazolen zur steigerung der stresstoleranz in pflanzen |
CN109563057B (zh) * | 2016-05-31 | 2022-06-24 | 大鹏药品工业株式会社 | 磺酰胺化合物或其盐 |
US10889555B2 (en) * | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
CN110545848A (zh) | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | 用于治疗具有肠外表现的炎症性肠病的化合物和方法 |
SG11202006255UA (en) | 2018-02-02 | 2020-07-29 | Univ Kyoto | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability |
WO2020051378A1 (en) | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05194412A (ja) | 1991-12-28 | 1993-08-03 | Advance Co Ltd | ジアゾリン化合物 |
GB9202791D0 (en) | 1992-02-11 | 1992-03-25 | British Bio Technology | Compounds |
BR9509024A (pt) | 1994-09-26 | 1997-09-30 | Shionogi & Co | Derivados de imidazol |
WO2001077089A1 (en) | 2000-04-06 | 2001-10-18 | Astrazeneca Ab | New neurokinin antagonists for use as medicaments |
CA2421893A1 (en) | 2000-08-31 | 2002-03-07 | Merck And Co., Inc. | Phosphate derivatives as immunoregulatory agents |
JP2002212070A (ja) * | 2001-01-24 | 2002-07-31 | Ono Pharmaceut Co Ltd | アスパラギン酸誘導体を有効成分として含有するスフィンゴシン−1−リン酸拮抗剤 |
JP2002332278A (ja) | 2001-05-08 | 2002-11-22 | Human Science Shinko Zaidan | Edg受容体拮抗作用を有する複素環誘導体 |
GB0113524D0 (en) | 2001-06-04 | 2001-07-25 | Hoffmann La Roche | Pyrazole derivatives |
DE10130397A1 (de) | 2001-06-23 | 2003-01-09 | Bayer Cropscience Gmbh | Herbizide substituierte Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbzide und Pflanzenwachstumsregulatoren |
JP4035759B2 (ja) | 2001-11-06 | 2008-01-23 | 独立行政法人産業技術総合研究所 | アミノアルコールリン酸化合物、製造方法、及びその利用方法 |
AU2003218056A1 (en) | 2002-03-01 | 2003-09-16 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
CA2477423A1 (en) | 2002-03-01 | 2003-09-12 | Merck & Co., Inc. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
KR20120125398A (ko) * | 2002-05-16 | 2012-11-14 | 노파르티스 아게 | 암에서 edg 수용체 결합제의 용도 |
CA2488117A1 (en) | 2002-06-17 | 2003-12-24 | Merck & Co., Inc. | 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists |
JP4335136B2 (ja) * | 2002-08-09 | 2009-09-30 | メルク エンド カムパニー インコーポレーテッド | チロシンキナーゼ阻害薬 |
CA2497067A1 (en) * | 2002-09-13 | 2004-03-25 | Novartis Ag | Amino-propanol derivatives |
TW200423930A (en) | 2003-02-18 | 2004-11-16 | Hoffmann La Roche | Non-nucleoside reverse transcriptase inhibitors |
US7425631B2 (en) | 2003-04-10 | 2008-09-16 | Amgen Inc. | Compounds and methods of use |
EP1615637A1 (en) * | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Pharmaceutical use of substituted 1,2,4-triazoles |
US20060252741A1 (en) | 2003-05-15 | 2006-11-09 | Colandrea Vincent J | 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists |
WO2005123677A1 (en) | 2004-06-16 | 2005-12-29 | Actelion Pharmaceuticals Ltd | 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents |
CN1993333B (zh) | 2004-08-04 | 2012-08-01 | 大正制药株式会社 | 三唑衍生物 |
BRPI0500778B1 (pt) | 2005-02-03 | 2014-07-29 | Krupinite Corp Ltd | Beneficiamento químico de matéria-prima contendo Tântalo-Nióbio |
CN101141878A (zh) | 2005-03-16 | 2008-03-12 | 巴斯福股份公司 | 联苯-n-(4-吡啶基)甲基磺酰胺 |
TW200736234A (en) | 2006-01-17 | 2007-10-01 | Astrazeneca Ab | Chemical compounds |
US8022091B2 (en) | 2006-02-03 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd. | Triazole derivative |
EP1988081B1 (en) | 2006-02-06 | 2012-10-17 | Taisho Pharmaceutical Co., Ltd | Binding inhibitor of sphingosine-1-phosphate |
US8097644B2 (en) | 2006-03-28 | 2012-01-17 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist |
JP2009534365A (ja) | 2006-04-21 | 2009-09-24 | アストラゼネカ アクチボラグ | Adg受容体修飾物質として有用なスルホンアミド化合物 |
US20090105324A1 (en) | 2006-04-21 | 2009-04-23 | Astrazeneca Ab | Imidazole derivatives for use as edg-1 antagonists |
-
2005
- 2005-08-04 CN CN2005800264032A patent/CN1993333B/zh not_active Expired - Fee Related
- 2005-08-04 RU RU2007107940/04A patent/RU2383536C2/ru not_active IP Right Cessation
- 2005-08-04 WO PCT/JP2005/014351 patent/WO2006013948A1/ja active Application Filing
- 2005-08-04 US US11/659,103 patent/US8022225B2/en not_active Expired - Fee Related
- 2005-08-04 EP EP05768756A patent/EP1798226A4/en not_active Withdrawn
- 2005-08-04 JP JP2006531560A patent/JP4993407B2/ja not_active Expired - Fee Related
-
2007
- 2007-12-12 HK HK07113536.7A patent/HK1107977A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN1993333B (zh) | 2012-08-01 |
JPWO2006013948A1 (ja) | 2008-05-01 |
US8022225B2 (en) | 2011-09-20 |
US20090131438A1 (en) | 2009-05-21 |
EP1798226A4 (en) | 2009-06-17 |
EP1798226A1 (en) | 2007-06-20 |
CN1993333A (zh) | 2007-07-04 |
JP4993407B2 (ja) | 2012-08-08 |
RU2007107940A (ru) | 2008-09-10 |
WO2006013948A1 (ja) | 2006-02-09 |
RU2383536C2 (ru) | 2010-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1107977A1 (en) | Triazole derivative | |
IL180331A0 (en) | 3-carbamoyl - 2 - pyridone derivative | |
TWI369356B (en) | Tetrahydropyridoindole derivatives | |
HK1091204A1 (en) | Heteroarylcarbamoylbenzene derivative | |
IL180481A0 (en) | Aryl-pyridine derivatives | |
EP1871766A4 (en) | TRIAZONE DERIVATIVES WITH ANTIPILY EFFECT | |
IL179736A0 (en) | Pyrrazolo-pyrimidine derivatives | |
EP1942105A4 (en) | AMINODIHYDROTHIAZINE DERIVATIVE | |
IL176562A0 (en) | Amidopyrazole derivative | |
IL192286A0 (en) | Triazole derivatives | |
HK1131128A1 (en) | Triazole derivative | |
ZA200703172B (en) | Imidazo-benzodiazepine derivatives | |
HK1100002A1 (en) | 4-phenyl-pyrimidine-2-carbonitrile derivatives | |
EP1951705A4 (en) | NEW ANTIFUNGAL TRIAZOLE DERIVATIVES | |
HK1100775A1 (en) | 4-Amino-5-cyanopyrimidine derivatives | |
GB0414272D0 (en) | OsK1 derivatives | |
IL180889A0 (en) | Pyrazole derivative | |
HK1115123A1 (en) | Pyridylmethylsulfone derivative | |
EP1914232A4 (en) | 2-OXOIMIDAZOLE DERIVATIVE WITH N-DIHYDROXYALKYL SUBSTITUTION | |
IL182001A0 (en) | 2-acylaminothiazole derivatives | |
GB0406137D0 (en) | Substituted pyrazoles | |
GB0409502D0 (en) | Triazole derivatives | |
GB0415888D0 (en) | Triazole derivatives | |
GB0408789D0 (en) | Triazole derivatives | |
AU2003280821A8 (en) | Beauveriolide derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20160804 |